In the single‐arm phase II LUMINOSITY trial (NCT03539536), ABBV‐399 demonstrated promising results in the treatment of MET protein overexpressing, EGFR WT, advanced/metastatic non‐squamous NSCLC. Here, MET is linked to non-small cell lung carcinoma.